Table 4.
Changes in echocardiographic parameters for right heart morphology and function before and after beraprost sodium administration.
| Variables | BPS 5 μg/kg | BPS 15 μg/kg | BPS 25 μg/kg | |||
|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | |
| PA/Ao | 0.9 ± 0.1 | 0.9 ± 0.1 | 1.0 ± 0.0 | 1.0 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.1 |
| RVEDA index (cm2/kg0.624) | 1.3 ± 0.2 | 1.4 ± 0.2 | 1.4 ± 0.3 | 1.4 ± 0.3 | 1.3 ± 0.3 | 1.4 ± 0.2 |
| RVESA index (cm2/kg0.628) | 0.9 ± 0.2 | 0.9 ± 0.2 | 1.0 ± 0.2 | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.9 ± 0.2 |
| RVIDd index (mm/kg0.327) | 18.6 ± 3.0 | 19.5 ± 3.4 | 19.0 ± 4.0 | 18.4 ± 3.0 | 18.2 ± 2.6 | 18.7 ± 3.9 |
| TAPSEn (mm/kg0.284) | 5.6 ± 0.8 | 6.0 ± 0.9* | 5.3 ± 0.8 | 6.1 ± 0.7* | 5.7 ± 0.9 | 6.2 ± 1.1* |
| RV FACn (%/kg−0.097) | 37.9 ± 8.8 | 41.1 ± 5.9 | 38.8 ± 8.4 | 45.9 ± 7.1* | 40.3 ± 9.0 | 45.4 ± 7.3* |
| RV s' (cm/s) | 9.6 ± 2.5 | 10.9 ± 2.2 | 10.1 ± 2.5 | 10.9 ± 1.9 | 11.6 ± 2.3 | 10.4 ± 2 |
| RV SV (mL/m2) | 48.3 ± 12.7 | 53.0 ± 10.5* | 45 ± 12.7 | 54.5 ± 13.8* | 48.1 ± 8.9 | 56.8 ± 12.8* |
| RV CO (L/min/m2) | 4.3 ± 1.3 | 5.0 ± 1.5 | 3.9 ± 0.8 | 4.9 ± 1.6* | 4.1 ± 1.0 | 5.1 ± 2.1* |
| RV-SL3seg (%) | 19.1 ± 3.3 | 22.4 ± 3.7* | 21.1 ± 4.2 | 23.1 ± 4.0* | 18.6 ± 3.8 | 20.7 ± 4.4* |
| RV-SL6seg (%) | 15.4 ± 3.1 | 18.2 ± 2.4* | 17.0 ± 3.5 | 18.8 ± 2.9* | 15.8 ± 3.8 | 17.1 ± 3.0* |
| RV-SrL3seg (%/s) | 2.4 ± 0.7 | 2.4 ± 0.6 | 2.2 ± 0.6 | 2.5 ± 0.7 | 2.3 ± 0.5 | 2.3 ± 0.5 |
| RV-SrL6seg (%/s) | 1.9 ± 0.5 | 1.9 ± 0.3 | 1.8 ± 0.4 | 2.1 ± 0.4* | 1.9 ± 0.5 | 1.9 ± 0.4 |
3seg, only right ventricular free wall analysis; 6seg, right ventricular global analysis; BPS, beraprost sodium; CO, cardiac output normalized by body surface area; PA/Ao, pulmonary artery to aortic diameter ratio; RV, right ventricular; RV FACn, RV fractional area change normalized by body weight; RV s', tissue Doppler imaging-derived peak systolic myocardial velocity of lateral tricuspid annulus; RVEDA index, end-diastolic RV area normalized by body weight; RVESA index, end-systolic RV area normalized by body weight; RVIDd index, end-diastolic RV internal dimension normalized by body weight; RV-SL, RV longitudinal strain; RV-SrL, RV longitudinal strain rate; RVWTd, end-diastolic RV wall thickness; SV, stroke volume normalized by body surface area; TAPSEn, tricuspid annular plane systolic excursion normalized by body weight.
Continuous variables were displayed as mean ± standard deviation.
The value is significantly different from pre-examination of the corresponding dose of BPS (p < 0.050).